利拉鲁肽与二甲双胍对肥胖患者2型糖尿病的疗效及其对微炎症状态的影响评价

Efficacy of Liraglutide and Metformin on Type 2 Diabetes in Obese Patients and Its Effect on Microinflammation

目的探究将利拉鲁肽联合二甲双胍应用于治疗肥胖2型糖尿病患者中的治疗效果,分析其对患者机体微炎症状造成的影响。方法该次研究实验时段设置为2016年4月—2017年12月,在该时段内对该院数据库进行调查分析,录入其中所有肥胖2型糖尿病患者个体资料,录入其中68例符合该次实验要求的患者作为实验对象,随机均分为对照组与实验组单组样本量设置为34。对照组患者单纯应用二甲双胍进行糖尿病常规治疗,实验组患者则在对照组的用药基础上加用利拉鲁肽进行治疗。对比两组患者治疗完成后的血糖状况以及体内炎症指标数据,评价两组患者的治疗效果。结果治疗完成后,实验组患者的血糖水平[(9.61±1.9)mmol/L、(12.25±2.5)mmol/L、(7.68±0.39)%]经对比分析优于对照组[(6.65±2.3)mmol/L、(8.26±2.3)mmol/L、(6.14±0.35)%],组间差异有统计学意义(t=5.785、6.849、17.136,P=0.000、0.000、0.000)。同时在治疗完成后,实验组患者的炎症指标[(15.32±2.1)nmol/L、(19.14±1.6)mg/dL、(17.61±2.98)pg/mL]较对照组[(12.14±2.0)nmol/L、(12.35±1.2)mg/dL、(1.39±3.21)pg/mL]来说有明显改善,数据对比差异有统计学意义(t=3.446、19.796、6.949,P=0.001、0.000、0.000)。结论在对肥胖2-型糖尿病患者进行治疗时,应用利拉鲁肽联合二甲双胍进行治疗,能够有效改善患者的高血糖状况,同时还能改善患者的炎症指标,有积极意义,是一种有效且安全的治疗方案值得推广使用。

Objective To explore the therapeutic effect of liraglutide combined with metformin in the treatment of obese patients with type 2 diabetes,and to analyze its effect on patients with micro-inflammatory symptoms.Methods The experimental period of this study was set from April 2016 to December 2017.During this period,the database of our hospital was investigated and analyzed,and the individual data of all obese type 2 diabetes patients were entered,and 68 of them were entered to meet the requirements of the experiment The patients were randomly divided into the control group and the experimental group.The single sample size was set to 34.Patients in the control group were treated with metformin alone for routine diabetes treatment,while patients in the experimental group were treated with liraglutide on the basis of the control group.Comparing the blood glucose status of the two groups of patients after the treatment and the data of inflammation indicators in vivo,the therapeutic effect of the two groups of patients was evaluated.Results After the treatment was completed,the blood glucose level of the experimental group[(9.61±1.9)mmol/L,(12.25±2.5)mmol/L,(7.68±0.39)%]was better than the control group[(6.65±2.3)mmol/L,(8.26±2.3)mmol/L,(6.14±0.35)%],the difference between the groups was statistically significant(t=5.785,6.849,17.136,P=0.000,0.000,0.000).At the same time,after the treatment was completed,the inflammation indexes of the experimental group[(15.32±2.1)nmol/L,(19.14±1.6)mg/dL,(17.61±2.980)pg/mL]were higher than those of the control group[(12.14±2.0)nmol/L,(12.35±1.2)mg/dL,(1.39±3.21)pg/mL]There is a significant improvement,and the difference in data comparison is statistically significant(t=3.446,19.796,6.949,P=0.001,0.000,0.000).Conclusion In the treatment of obese type 2 diabetes patients,the use of liraglutide combined with metformin treatment can effectively improve the patient's hyperglycemia status,and at the same time can improve the patient's inflammation indicators,has a positive significance,is an effective and The safe treatment plan is worth popularizing.